Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
- Published In:
- JAMA, 330(6), 512-527 (2023)
- Authors:
- Sims, John R, Zimmer, Jennifer A, Evans, Cynthia D, Lu, Ming, Ardayfio, Paul, Sparks, JonDavid, Wessels, Alette M, Shcherbinin, Sergey, Wang, Hong, Monkul Nery, Emel Serap, Collins, Emily C, Solomon, Paul, Salloway, Stephen, Apostolova, Liana G, Hansson, Oskar, Ritchie, Craig, Brooks, Dawn A, Mintun, Mark, Skovronsky, Daniel M
- Database ID:
- RPEP-07393
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-07393APA
Sims, John R; Zimmer, Jennifer A; Evans, Cynthia D; Lu, Ming; Ardayfio, Paul; Sparks, JonDavid; Wessels, Alette M; Shcherbinin, Sergey; Wang, Hong; Monkul Nery, Emel Serap; Collins, Emily C; Solomon, Paul; Salloway, Stephen; Apostolova, Liana G; Hansson, Oskar; Ritchie, Craig; Brooks, Dawn A; Mintun, Mark; Skovronsky, Daniel M. (2023). Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.. JAMA, 330(6), 512-527. https://doi.org/10.1001/jama.2023.13239
MLA
Sims, John R, et al. "Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.." JAMA, 2023. https://doi.org/10.1001/jama.2023.13239
RethinkPeptides
RethinkPeptides Research Database. "Donanemab in Early Symptomatic Alzheimer Disease: The TRAILB..." RPEP-07393. Retrieved from https://rethinkpeptides.com/research/sims-2023-donanemab-in-early-symptomatic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.